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Curbing hepatitis C virus spread in Egypt
Hepatitis C virus (HCV) is a parenterally transmitted 
pathogen that has infected about 185 million people 
worldwide1 and is a major cause of cirrhosis and 
hepatocellular carcinoma. The recent advent of direct-
acting antivirals1 has revolutionised the treatment of 
hepatitis C. Direct-acting antivirals achieve a permanent 
cure in over 90% of cases and have little or no side-eﬀ ects.1 
Treatment schedules are simple and short, with little or no 
monitoring needed. Thus, direct-acting antivirals will soon 
make obsolete present regimens containing interferon 
alfa and ribavirin, which have frustrated patients and 
health-care providers alike for years with their meagre 
eﬀ ectiveness and poor safety proﬁ les. 
In resource-rich countries, HCV prevalence is low: 
most new infections occur among people who inject 
drugs, whereas older infections were established 
iatrogenically—ie, via blood transfusions and invasive 
medical procedures. This route has been virtually 
eliminated by the introduction of standard safety 
procedures and an improved awareness of blood-borne 
pathogens. Unfortunately, unsafe injections continue 
to occur in developing areas, in which up to 75% of 
injections are still done with insuﬃ  ciently sterilised 
equipment.2 Unsafe injections have been estimated to 
transmit 8–16 million hepatitis B virus, 2·3–4·7 million 
HCV, and 80 000–160 000 HIV infections every year.3
In Egypt, HCV prevalence is about 15% among adults 
and incidence is about 150 000 new cases per year.4 These 
high rates are due to the mass campaign of intravenous 
anti-schistosomiasis treatment in the 1960s–80s.5 From 
this original pool of infected individuals, HCV spread 
to large swathes of the population because of various 
unsafe invasive procedures—a problem that still persists. 
In The Lancet Global Health, Romulus Breban and 
colleagues6 use mathematical modelling to estimate 
the eﬀ ect of combined preventive and therapeutic 
interventions on the self-sustained spread of HCV 
in Egypt. Findings are expressed as R0—the basic 
reproduction number—which corresponds to the 
number of new infections that an index case generates 
in an uninfected population. If everybody accessed 
health-care facilities for injections and invasive 
medical procedures according to the average rates 
derived from ﬁ eld data, the R0 would be 1 or lower and 
HCV transmission would not be self-sustained. The 
R0 of the spread of HCV without treatment was 3·54 
(95% CI 1·28–6·18). The investigators conclude that 
a small core group of patients who receive frequent 
health-care interventions maintain the spread of 
HCV via a higher than mean rate of unsafe injections, 
infecting, as a result, several people who access the 
same facilities. 
The investigators then estimate the eﬀ ect of 
implementation of an enhanced injection control 
programme or increased antiviral treatment uptake, 
both untargeted or targeted to heavy injectors, and 
given early during the course of infection or later 
on. Targeting the core group of heavy injectors with 
treatment with greater than 80% eﬃ  cacy given within 
2·5 years of chronic infection would have impressive 
beneﬁ cial eﬀ ects. Therefore, the investigators advocate 
screening of all patients with chronic disorders who 
undergo frequent injections for HCV; education of 
uninfected individuals about safe injection procedures 
and reduction of unnecessary injections; and treatment 
of those infected with highly eﬀ ective regimens. 
Furthermore, since an early treatment approach 
(within 2·5 years of chronic infection) would be more 
eﬀ ective than a late treatment approach (within 
15 years), the investigators suggest a periodic screening 
programme (every 5 years) among patients with chronic 
disorders to identify rapidly those who seroconvert and 
to treat them immediately. Thus, targeted interventions 
would be more successful in reducing HCV transmission 
than mass interventions; a similar method has been 
implemented in the past among sex workers to reduce 
HIV prevalence in Thailand.7
Treatment as prevention is not a new notion in the 
management of infectious diseases—it has been applied 
with success in communities aﬀ ected by HIV.8 Models 
have also been developed to curb the spread of HCV 
among people who inject drugs,9 and can be applied to 
other settings in which the spread of HCV is particularly 
high, such as HIV-infected men who have sex with 
men10 or prison inmates.11 The successful application 
of these models depends on the integration of several 
approaches. Among people who inject drugs, HCV 
prevalence can only be reduced by combining eﬃ  cacious 
treatments with opiate substitution and syringe 
exchange programmes.9 
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Unfortunately, there have been no ﬁ eld studies to 
prove the eﬀ ectiveness of these approaches, and the 
high price of new direct-acting antivirals might curb 
widespread implementation of such programmes. 
Not surprisingly, companies have started reducing 
prices of HCV drugs through agreements with local 
governments. Costs will nonetheless aﬀ ect prioritisation 
of interventions: the work by Breban and colleagues6 
is a perfect example of how to identify such priorities. 
Such a model is of huge relevance for other developing 
regions, and even for other infectious diseases, 
especially when epidemics are driven by inappropriate 
health-care practices.
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